1. Home
  2. AHG vs NVAX Comparison

AHG vs NVAX Comparison

Compare AHG & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AHG

Akso Health Group ADS

N/A

Current Price

$2.00

Market Cap

1.7B

ML Signal

N/A

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.11

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AHG
NVAX
Founded
2013
1987
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
AHG
NVAX
Price
$2.00
$8.11
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$11.33
AVG Volume (30 Days)
14.4K
3.1M
Earning Date
08-14-2025
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
309.76
EPS
N/A
2.58
Revenue
N/A
$1,123,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.27
Revenue Growth
N/A
64.69
52 Week Low
$1.08
$5.80
52 Week High
$2.50
$11.85

Technical Indicators

Market Signals
Indicator
AHG
NVAX
Relative Strength Index (RSI) 43.58 40.20
Support Level $1.57 $8.01
Resistance Level $2.46 $8.45
Average True Range (ATR) 0.18 0.35
MACD -0.06 0.04
Stochastic Oscillator 22.03 29.30

Price Performance

Historical Comparison
AHG
NVAX

About AHG Akso Health Group ADS

Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: